Tvardi Therapeutics, Inc.
TVRD · XNASCIK 1346830fmd_1EJB88FC1J2CYKYETJN3JW7T3ZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 13 | 20 | 135 | 23 | 42 | 21 | 7 | – |
| Cost of revenue | – | – | – | – | – | 0 | – | – | – | – |
| Gross profit | – | – | – | – | – | 23 | – | – | – | – |
| Research and development | 49 | 49 | 76 | 114 | 108 | 83 | 92 | 109 | 24 | 18 |
| Total operating expenses | 58 | 60 | 91 | 132 | 130 | 112 | 129 | 142 | 28 | 27 |
| Operating income | (58) | (59) | (77) | (112) | 5 | (89) | (88) | (121) | (28) | (27) |
| Interest and investment income | – | – | – | – | – | – | – | – | 1 | 1 |
| Other non-operating income (expense) | 1 | 1 | 3 | 4 | 2 | 1 | 2 | 4 | (2) | 7 |
| Income before taxes | (58) | (58) | (74) | (107) | 8 | (88) | (85) | (119) | (71) | – |
| Income tax expense | (0) | (0) | (0) | (1) | (1) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (57) | (58) | (74) | (106) | 8 | (88) | (85) | (119) | (71) | – |
| Net income | (57) | (58) | (74) | (106) | 8 | (88) | (85) | (119) | (29) | (18) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (29) | (18) |